BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 26138695)

  • 1. Immunotherapy of HPV-associated cancer: DNA/plant-derived vaccines and new orthotopic mouse models.
    Venuti A; Curzio G; Mariani L; Paolini F
    Cancer Immunol Immunother; 2015 Oct; 64(10):1329-38. PubMed ID: 26138695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy in new pre-clinical models of HPV-associated oral cancers.
    Paolini F; Massa S; Manni I; Franconi R; Venuti A
    Hum Vaccin Immunother; 2013 Mar; 9(3):534-43. PubMed ID: 23296123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HPV 16 E5 oncoprotein is expressed in early stage carcinogenesis and can be a target of immunotherapy.
    Paolini F; Curzio G; Cordeiro MN; Massa S; Mariani L; Pimpinelli F; de Freitas AC; Franconi R; Venuti A
    Hum Vaccin Immunother; 2017 Feb; 13(2):291-297. PubMed ID: 27929754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy for human papillomavirus-associated disease and cervical cancer: review of clinical and translational research.
    Lee SJ; Yang A; Wu TC; Hung CF
    J Gynecol Oncol; 2016 Sep; 27(5):e51. PubMed ID: 27329199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimal induction of HPV DNA vaccine-induced CD8+ T cell responses and therapeutic antitumor effect by antigen engineering and electroporation.
    Seo SH; Jin HT; Park SH; Youn JI; Sung YC
    Vaccine; 2009 Sep; 27(42):5906-12. PubMed ID: 19651174
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human papillomavirus immunogen that provides protective tumor immunity and induces tumor regression.
    Marquez JP; Rivera R; Kang KH; Gardner MB; Torres JV
    Viral Immunol; 2012 Apr; 25(2):141-52. PubMed ID: 22486305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human papillomavirus vaccines for the prevention and treatment of cervical cancer.
    Tomson TT; Roden RB; Wu TC
    Curr Opin Investig Drugs; 2004 Dec; 5(12):1247-61. PubMed ID: 15648945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-lasting immunoprotective and therapeutic effects of a hyperstable E7 oligomer based vaccine in a murine human papillomavirus tumor model.
    Cerutti ML; Alonso LG; Tatti S; de Prat-Gay G
    Int J Cancer; 2012 Apr; 130(8):1813-20. PubMed ID: 21780110
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current therapeutic vaccination and immunotherapy strategies for HPV-related diseases.
    Skeate JG; Woodham AW; Einstein MH; Da Silva DM; Kast WM
    Hum Vaccin Immunother; 2016 Jun; 12(6):1418-29. PubMed ID: 26835746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine.
    Welters MJ; Kenter GG; Piersma SJ; Vloon AP; Löwik MJ; Berends-van der Meer DM; Drijfhout JW; Valentijn AR; Wafelman AR; Oostendorp J; Fleuren GJ; Offringa R; Melief CJ; van der Burg SH
    Clin Cancer Res; 2008 Jan; 14(1):178-87. PubMed ID: 18172269
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA-based immunotherapy for HPV-associated head and neck cancer.
    Aggarwal C
    Immunotherapy; 2016 Oct; 8(10):1187-92. PubMed ID: 27605067
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced therapeutic effects conferred by an experimental DNA vaccine targeting human papillomavirus-induced tumors.
    Diniz MO; Cariri FA; Aps LR; Ferreira LC
    Hum Gene Ther; 2013 Oct; 24(10):861-70. PubMed ID: 24007495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DNA vaccines for cervical cancer: from bench to bedside.
    Hung CF; Monie A; Alvarez RD; Wu TC
    Exp Mol Med; 2007 Dec; 39(6):679-89. PubMed ID: 18160838
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polymeric nanoparticles for co-delivery of synthetic long peptide antigen and poly IC as therapeutic cancer vaccine formulation.
    Rahimian S; Fransen MF; Kleinovink JW; Christensen JR; Amidi M; Hennink WE; Ossendorp F
    J Control Release; 2015 Apr; 203():16-22. PubMed ID: 25660830
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human papillomavirus vaccines for the treatment of cervical cancer.
    Sin JI
    Expert Rev Vaccines; 2006 Dec; 5(6):783-92. PubMed ID: 17184217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel, broad spectrum therapeutic HPV vaccine targeting the E7 proteins of HPV16, 18, 31, 45 and 52 that elicits potent E7-specific CD8T cell immunity and regression of large, established, E7-expressing TC-1 tumors.
    Wick DA; Webb JR
    Vaccine; 2011 Oct; 29(44):7857-66. PubMed ID: 21816200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel self-assembled nanoparticle vaccine with HIV-1 Tat₄₉₋₅₇/HPV16 E7₄₉₋₅₇ fusion peptide and GM-CSF DNA elicits potent and prolonged CD8⁺ T cell-dependent anti-tumor immunity in mice.
    Tang J; Yin R; Tian Y; Huang Z; Shi J; Fu X; Wang L; Wu Y; Hao F; Ni B
    Vaccine; 2012 Feb; 30(6):1071-82. PubMed ID: 22178528
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic effect of programmed cell death protein 1 blockade and secondary lymphoid tissue chemokine in the induction of anti-tumor immunity by a therapeutic cancer vaccine.
    Moeini S; Saeidi M; Fotouhi F; Mondanizadeh M; Shirian S; Mohebi A; Gorji A; Ghaemi A
    Arch Virol; 2017 Feb; 162(2):333-346. PubMed ID: 27699512
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic human papillomavirus vaccination.
    Albers AE; Kaufmann AM
    Public Health Genomics; 2009; 12(5-6):331-42. PubMed ID: 19684445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Moving forward with human papillomavirus immunotherapies.
    Çuburu N; Schiller JT
    Hum Vaccin Immunother; 2016 Nov; 12(11):2875-2880. PubMed ID: 27388123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.